Kymera Therapeutics, Inc. $KYMR Shares Bought by Rhumbline Advisers

Rhumbline Advisers grew its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 9.0% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,928 shares of the company’s stock after purchasing an additional 5,771 shares during the period. Rhumbline Advisers owned approximately 0.11% of Kymera Therapeutics worth $1,914,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. State of Wyoming purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics during the fourth quarter worth $55,000. KBC Group NV increased its position in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after acquiring an additional 328 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics during the first quarter worth $68,000. Finally, Advisors Asset Management Inc. increased its position in shares of Kymera Therapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock worth $136,000 after acquiring an additional 2,230 shares during the period.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $48.12 on Thursday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $53.27. The company has a market capitalization of $3.44 billion, a price-to-earnings ratio of -13.87 and a beta of 2.17. The firm has a 50-day simple moving average of $43.63 and a 200-day simple moving average of $37.61.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. During the same quarter last year, the company posted ($0.58) EPS. Kymera Therapeutics’s quarterly revenue was down 55.1% on a year-over-year basis. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on KYMR. The Goldman Sachs Group raised Kymera Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 15th. Oppenheimer reissued an “outperform” rating and issued a $53.00 target price (down previously from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. Bank of America raised Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 target price on the stock in a report on Monday, June 2nd. Guggenheim reissued a “buy” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, June 3rd. Finally, Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $59.42.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Bvf Partners L. P/Il acquired 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The stock was purchased at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. This trade represents a 12.78% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Bruce N. Jacobs sold 79,220 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total transaction of $3,961,000.00. Following the completion of the sale, the chief financial officer owned 227,409 shares of the company’s stock, valued at approximately $11,370,450. The trade was a 25.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 16.01% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.